Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting
Muntañola, Ana (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Arguiñano, José M (Hospital Universitario de Navarra)
Dávila, Julio (Complejo Asistencial de Ávila)
de Villambrosia, Sonia González (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina)
Jiménez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid))
Salar, Antonio (Universitat Pompeu Fabra)

Data:	2022
Resum:	Although rituximab is generally well-tolerated, infusion-related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low-speed infusion rates have been recommended. Consequently, intravenous (i. v. ) infusion of rituximab can become a labor-intensive process. Rapid i. v. rituximab infusion over 90 min has demonstrated a favorable safety profile for the second and subsequent infusions during the course of therapy. The aim of this study was to investigate the safety and tolerability of 90-min rapid infusion of Sandoz rituximab biosimilar (SDZ-RTX) for patients with CD20+ lymphoma or chronic lymphocytic leukemia (CLL). We retrospectively reviewed all patients with CD20+ lymphoma or CLL who received SDZ-RTX infusions in 90 min from July 2019 to July 2021 at seven Spanish hospitals. The primary end point was the incidence of IRRs. We identified 124 patients and 576 rapid administrations of SDZ-RTX, with an average of five rapid infusions per patient. Most rapid infusions of SDZ-RTX were in combination with CHOP/CHOP-like therapy (48. 4%), followed by SDZ-RTX alone (15. 1%), in combination with bendamustine (14. 5%), or with other regimens (22%). The 90-min SDZ-RTX infusion schedule was well-tolerated with no grade 3/4 IRRs. The incidence of any grade IRR during the first rapid infusion was 1% (5 grade 1 IRRs and 1 grade 2 IRR). In conclusion, rapid 90-min i. v. administration of SDZ-RTX for the second and subsequent infusions during the course of therapy is well-tolerated in patients with CD20+ lymphoma or CLL.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Clinical and Translational Science, Vol. 16 (november 2022) , p. 305-312, ISSN 1752-8062

DOI: 10.1111/cts.13450
PMID: 36385738

8 p, 132.9 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats